Ultromics Lands $55M Series C to Tackle Undiagnosed Heart Failure at Scale

Ultromics has raised $55 million in a Series C financing round co-led by L&G, Allegis Capital and Lightrock. Continued support came from Oxford Science Enterprises, GV, Blue Venture Fund, and Oxford University.

Major U.S. health systems, including UChicago Medicine’s venture investment vehicle (UCM Ventures), and UPMC Enterprises, also participated in the round. 

Built on years of clinical study and hundreds of thousands of echo scans, Ultromics offers the first U.S. Food and Drug Administration (FDA)-cleared, Medicare-reimbursed artificial intelligence (AI) technology to help clinicians detect HFpEF and cardiac amyloidosis, two of the most elusive forms of heart failure. The company is now expanding across the United States to bring that capability to hospitals and echo labs with the highest volume of at-risk patients, aiming to make AI-enhanced diagnostics a default step in the cardiac workup. Ultromics is also expanding its pipeline to include additional cardiac conditions, new distribution channels and deeper partnerships with health systems and clinical leaders. 

“Ultromics has established itself as an early-mover in the large and underserved cardiovascular disease market, having developed one of the first commercially available AI-powered diagnostic echocardiogram technologies,” said Alastair Stewart, head of Investments, Venture Capital, at L&G. “This successful Series C round is a testament to the massive opportunity for cutting-edge technology to transform how clinicians can detect and treat serious cardiovascular diseases that impact millions of people every year.”

It’s a critical moment for cardiovascular care. Heart failure is rising, costs are mounting and millions of patients are still going undiagnosed, especially those with harder-to-detect forms like HFpEF and cardiac amyloidosis. In the United States alone, heart failure drives more than $30 billion in annual healthcare costs, a number projected to exceed $70 billion by 2030. Clinicians often rely on subjective interpretation of echocardiograms, leading to missed or delayed diagnoses even when patients are actively seeking care. In fact, up to 64% of HFpEF cases go undiagnosed, and cardiac amyloidosis is frequently mistaken for more common forms of heart disease, leaving patients untreated until symptoms worsen or irreversible damage occurs.  

Ultromics addresses this diagnostic blind spot by using AI to extract hidden disease signals from standard echocardiograms, enabling earlier, more accurate detection of complex heart conditions—without requiring new hardware or disrupting clinical workflows. Its FDA-cleared EchoGo platform supports HFpEF and cardiac amyloidosis diagnoses. Trained and validated on one of the largest real-world echo datasets globally, EchoGo generates real-time probability scores to help cardiologists identify high-risk patients earlier than traditional methods. EchoGo is fully reimbursed under Medicare, making it scalable across hospitals, clinics, and health systems nationwide. 

“The reality is, hospitals already have the data, they just haven’t had the tools to extract the more subtle diagnostic signals from it. By analyzing routine echocardiograms with AI, we’re helping clinicians identify high-risk patients earlier, enabling intervention before disease progresses,” Ultromics Founder/CEO Ross Upton, Ph.D., stated. “We’ve spent years building our platform to fit into clinical workflows, with no extra hardware and no new friction, and this funding helps us scale that across the U.S. at a moment when health systems are actively looking to combat the growing heart failure crisis.”

Ultromics has already analyzed more than 430,000 echocardiograms to date. In clinical studies, EchoGo improved HFpEF detection by 73.6% when compared with standard clinical risk scores. The company’s latest diagnostic model for cardiac amyloidosis, validated in a global study of 18 institutions and published in the European Heart Journal, outperformed current clinical risk scores while distinguishing disease from similar conditions. 

With growing adoption and partnerships across flagship institutions, including UChicago Medicine, University Hospitals Cleveland, Northwestern, and Mayo Clinic, Ultromics is building regional clusters of clinical and commercial traction, particularly in high-prevalence regions like the U.S. Midwest. Its platform is helping hospitals reduce unnecessary tests, streamline workflows and initiate treatment earlier so it’s more effective and less expensive.

“Heart failure and cardiac amyloidosis impact millions of lives and strain healthcare systems, despite new approaches that have the potential to significantly improve patient outcomes. There is a critical need for scalable solutions that enable earlier, more accurate diagnosis and elevate the standard of care,” Lightrock Partner Umur Hursever commented. “Ultromics’ AI-driven technology is already making a real-world impact, improving diagnostic accuracy, supporting clinical decisions, and expanding access to specialist care. The Lightrock team is delighted to support Ultromics’ mission and growing impact.”

Ultromics has rapidly expanded its platform capabilities and U.S. market presence during the past year. In late 2024, the company received FDA Breakthrough Device clearance for EchoGo Amyloidosis, followed in 2025 by the launch of EchoGo Score, a new feature that adds AI-driven probability scoring to EchoGo Heart Failure, helping clinicians detect HFpEF with greater nuance. These clinical advances are now supported by Medicare reimbursement for both outpatient and inpatient use, strengthening Ultromics’ foundation for scaled adoption across U.S. hospitals.

“There’s a long-standing blind spot in cardiology where millions of patients with treatable heart failure are missed because their symptoms are subtle and echo images are hard to interpret,” Allegis Capital Managing Director Victor Westerlind said. “What’s exciting about Ultromics is how they’re closing that gap. Their platform brings AI and cardiology together in a way that makes it easier for physicians to identify high-risk patients earlier. When paired with the latest treatment advances, it’s a diagnostic win that will help save lives.”

Founded out of the University of Oxford, Ultromics develops FDA-cleared, AI-powered tools that enhance echocardiographic diagnosis. Built in partnership with the NHS and Mayo Clinic, its EchoGo platform helps clinicians detect complex heart diseases earlier and more accurately—using only a standard ultrasound scan. Ultromics is backed by investors and U.S. healthcare systems.

Lightrock is a global investment platform committed to building a sustainable future. Operating across private and public markets, Lightrock manages more than $5.5 billion in assets and invests in Europe, North America, Latin America, Asia, and Africa. Lightrock is a certified B Corp. with a dedicated team of more than 130 professionals working across a network of six offices.

Established in 1836, L&G is one of the U.K.’s leading financial services groups and a major global investor, with £1.1 trillion in total assets under management (as of FY24) of which about 44% (£0.5 trillion) is international. The firm is a leading player in institutional retirement, in retail savings and protection, and in asset management through both public and private markets. Across the Group, the company is committed to responsible investing and dedicated to serving the long-term savings and investment needs of customers and society.

Allegis Capital is an early-stage venture capital firm partnering with companies that enable digital transformation across the enterprise. The firm supports founders with hands-on guidance, operational expertise, and access to a global network of industry leaders. With a long track record of building market-defining businesses, Allegis backs the teams and platforms reshaping the way in which work gets done. Headquartered in Palo Alto, Calif., Allegis has been investing in enterprise innovation for more than two decades.